Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

With that said, there is one program I want to zero in on, which is the development of its differentiated CD-19 CAR-T being developed to target patients with Myasthenia Gravis [MG]. The reason why ...

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

"All three types of myasthenia gravis, based on antibody status, can have similar symptoms," said Henry Kaminski, MD, of ...

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

Myasthenia gravis is a rare neuromuscular, autoimmune disease that impacts more than 90,000 individuals in the United States alone. The condition can impact patients at any age or stage in their ...

The American Oncology Institute (AOI) in Guntur has successfully treated a rare and complex case of Myasthenia Gravis ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help others.